Bristol-Myers reveals nivolumab-Yervoy combo study, finally
This article was originally published in Scrip
Executive Summary
All it took was a brief mention during a question-and-answer session, but Bristol-Myers Squibb reached a new high and its stock inched higher on 5 March after a Bristol-Myers executive revealed that the company will test its experimental PD1 inhibitor nivolumab in a Phase III lung cancer clinical trial with its approved melanoma blockbuster Yervoy (ipilimumab).